Overview

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Status:
RECRUITING
Trial end date:
2026-12-25
Target enrollment:
Participant gender:
Summary
The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.
Phase:
PHASE1
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
Peking University Shougang Hospital
Shandong Cancer Hospital and Institute